Indication
Non Small Cell Lung Cancer Metastatic
27 clinical trials
31 products
7 drugs
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
EtrumadenantProduct
ZimberelimabProduct
CarboplatinProduct
PemetrexedProduct
PembrolizumabClinical trial
Randomized, Multicenter, Multinational, Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) Versus Keytruda® in Subjects With Stage IV NSCLCStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing CancerStatus: Active (not recruiting), Estimated PCD: 2028-11-02
Product
cyclophosphamideProduct
IpilimumabProduct
NivolumabProduct
gavo-celProduct
fludarabineClinical trial
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic MelanomaStatus: Completed, Estimated PCD: 2020-11-16
Product
APX005MClinical trial
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic CancerStatus: Active (not recruiting), Estimated PCD: 2020-02-26
Product
NiraparibProduct
TSR-042Product
Carboplatin-PaclitaxelProduct
BevacizumabProduct
TSR-022Product
Carboplatin-PemetrexedProduct
Carboplatin-Nab-PaclitaxelProduct
LYL797Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
AcasunlimabClinical trial
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination Pembrolizumab Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint InhibitorStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2bStatus: Active (not recruiting), Estimated PCD: 2023-05-31
Product
DRP-104Clinical trial
Phase 1 and Phase 2a, First-in-human Study of DRP-104, a Glutamine Antagonist, in Adult Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-03-28
Product
UpifitamabProduct
atezolizumabClinical trial
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-28
Product
NintedanibClinical trial
A Phase II Single-group Assignment, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Tyrosine Kinase Inhibitor in Patients With Advanced ROS1-positive Non-small Cell Lung Cancer (ALBATROS)Status: Recruiting, Estimated PCD: 2025-03-01
Product
LorlatinibClinical trial
A Phase II, Multi-centre Study, to Evaluate the Efficacy and Safety of Osimertinib Treatment for Patients With EGFR-mutated Non-small Cell Lung Cancer (NSCLC) With Brain or Leptomeningeal MetastasesStatus: Active (not recruiting), Estimated PCD: 2023-03-15
Drug
OsimertinibClinical trial
A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLCStatus: Recruiting, Estimated PCD: 2025-12-09
Product
Anti-PD-(L)1Clinical trial
Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving DocetaxelStatus: Completed, Estimated PCD: 2021-02-01
Clinical trial
Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
TiragolumabDrug
AtezolizumabClinical trial
A Multicenter Single-arm Phase II Interventional Study to Evaluate the Activity and Safety of the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib.Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) OligoprogressionStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Standard of careClinical trial
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-09-21
Drug
CisplatinClinical trial
Effect of Diabetes Mellitus on Outcomes and Response Rate in Patients With Advanced NSCLC on ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of Pembrolizumab in Combination With Plinabulin and Docetaxel in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination With Platinum-doublet Chemotherapy (KeyPemls-004)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)Status: Terminated, Estimated PCD: 2022-03-11
Drug
LurbinectedinDrug
T-VECClinical trial
A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain MetastasesStatus: Withdrawn, Estimated PCD: 2027-08-01
Drug
JDQ443Clinical trial
A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-31
Clinical trial
Phase II Trial of Fecal Microbial Transplantation in Patients With Advanced Non-Small Cell Lung Cancer and Melanoma Treated With Immune Checkpoint Inhibitors.Status: Active (not recruiting), Estimated PCD: 2024-09-01
Product
FMTClinical trial
A Phase II Non-randomized, Single Group Assignment, Open-label, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa TrialStatus: Completed, Estimated PCD: 2021-02-18
Clinical trial
An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2025-01-01